Skip to main content
Top
Published in: International Urology and Nephrology 1/2009

01-03-2009 | Urology - Original Paper

Rising incidence of renal cell carcinoma in Ireland

Authors: Opeyemi A. Falebita, Silvia Mancini, Eamonn Kiely, Harry Comber

Published in: International Urology and Nephrology | Issue 1/2009

Login to get access

Abstract

Objective

To determine the trend in the incidence of renal cell carcinoma in Ireland, and evaluate changes in the modes of presentation and outcomes.

Methods

Data on all histologically diagnosed renal cancers in Ireland over a 12-year period (1994–2005) were retrieved from the database of the National Cancer Registry of Ireland. Data on all renal cancer deaths in Ireland in the period 1994–2004 were obtained from the Central Statistics Office.

Results

There were 2,485 cases of renal cell carcinoma from 1994 to 2005, of which 64% were in males and 36% in females. The average age of females at diagnosis fell from 63 years in 1994 to 58 years in 2005, with little change in the average age in males. The age-adjusted incidence of renal cell carcinoma per 100,000 person-year increased from 5.2 in 1994 to 6.8 in 2005, an annual percentage change of +3.4%. The percentage of incidental renal cell carcinoma increased from 5% in 1999 to 21% in 2003. The age-adjusted mortality rate for males increased from 4.8 per 100,000 person-year in 1994 to 7.3 in 2004, while that for females decreased from 2.6 to 2.3 in the same period. There was no overall increase in survival over the study period.

Conclusion

While the incidence of renal cell carcinoma is increasing in Ireland, largely, but not entirely, due to an increase in incidentally diagnosed cancers, mortality is increasing in males only.
Literature
4.
go back to reference Liu S, Semenciw R, Morrison H et al (1997) Kidney cancer in Canada: the rapidly increasing incidence of adenocarcinoma in adults and seniors. Can J Public Health 88:99–104PubMed Liu S, Semenciw R, Morrison H et al (1997) Kidney cancer in Canada: the rapidly increasing incidence of adenocarcinoma in adults and seniors. Can J Public Health 88:99–104PubMed
8.
go back to reference Lindblad P (2004) Epidemiology of renal cell carcinoma. Scand J Surg 93:88–96PubMed Lindblad P (2004) Epidemiology of renal cell carcinoma. Scand J Surg 93:88–96PubMed
10.
go back to reference Sweeney JP, Thornhill JA, Graiger R et al (1996) Incidentally detected renal cell carcinoma: pathological features, survival trends and implications for treatment. Br J Urol 78:351–353PubMed Sweeney JP, Thornhill JA, Graiger R et al (1996) Incidentally detected renal cell carcinoma: pathological features, survival trends and implications for treatment. Br J Urol 78:351–353PubMed
12.
go back to reference Nunnally J World health statistics annual 1995. World Health Organization, Geneva Nunnally J World health statistics annual 1995. World Health Organization, Geneva
Metadata
Title
Rising incidence of renal cell carcinoma in Ireland
Authors
Opeyemi A. Falebita
Silvia Mancini
Eamonn Kiely
Harry Comber
Publication date
01-03-2009
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 1/2009
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-008-9413-0

Other articles of this Issue 1/2009

International Urology and Nephrology 1/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.